CN108732147B - Method for detecting apoptosis process based on FRET effect - Google Patents
Method for detecting apoptosis process based on FRET effect Download PDFInfo
- Publication number
- CN108732147B CN108732147B CN201810366318.XA CN201810366318A CN108732147B CN 108732147 B CN108732147 B CN 108732147B CN 201810366318 A CN201810366318 A CN 201810366318A CN 108732147 B CN108732147 B CN 108732147B
- Authority
- CN
- China
- Prior art keywords
- product
- donor
- reaction
- apoptosis
- prepare
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000006907 apoptotic process Effects 0.000 title claims abstract description 70
- 238000000034 method Methods 0.000 title claims abstract description 50
- 230000000694 effects Effects 0.000 title claims abstract description 35
- 238000002866 fluorescence resonance energy transfer Methods 0.000 title claims abstract description 34
- 230000008569 process Effects 0.000 title claims abstract description 26
- 239000000523 sample Substances 0.000 claims abstract description 56
- 238000006243 chemical reaction Methods 0.000 claims abstract description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 24
- 102000011727 Caspases Human genes 0.000 claims abstract description 22
- 108010076667 Caspases Proteins 0.000 claims abstract description 22
- 238000003384 imaging method Methods 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 229910052741 iridium Inorganic materials 0.000 claims abstract description 12
- 230000008859 change Effects 0.000 claims abstract description 8
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000010226 confocal imaging Methods 0.000 claims abstract description 4
- 239000003446 ligand Substances 0.000 claims description 16
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 claims description 7
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 claims description 6
- 108010075254 C-Peptide Proteins 0.000 claims description 6
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims description 6
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 6
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 claims description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 claims description 6
- TVRHRBCLLIUJDG-UHFFFAOYSA-N tetrazin-5-amine Chemical compound NC1=CN=NN=N1 TVRHRBCLLIUJDG-UHFFFAOYSA-N 0.000 claims description 6
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 claims description 6
- 238000006482 condensation reaction Methods 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- HULKIXRFKRCRHD-UHFFFAOYSA-N 4-[(2-acetamido-4-methylpentanoyl)amino]-5-[[1-[[3-carboxy-1-oxo-1-[[2-oxo-4-(trifluoromethyl)chromen-7-yl]amino]propan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound C=1C=C2C(C(F)(F)F)=CC(=O)OC2=CC=1NC(=O)C(CC(O)=O)NC(=O)C(NC(=O)C(CCC(O)=O)NC(=O)C(NC(C)=O)CC(C)C)CC1=CN=CN1 HULKIXRFKRCRHD-UHFFFAOYSA-N 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- -1 small molecule compound Chemical class 0.000 claims description 4
- LFIWXXXFJFOECP-UHFFFAOYSA-N 4-(aminomethyl)benzonitrile Chemical compound NCC1=CC=C(C#N)C=C1 LFIWXXXFJFOECP-UHFFFAOYSA-N 0.000 claims description 3
- NBPGPQJFYXNFKN-UHFFFAOYSA-N 4-methyl-2-(4-methylpyridin-2-yl)pyridine Chemical compound CC1=CC=NC(C=2N=CC=C(C)C=2)=C1 NBPGPQJFYXNFKN-UHFFFAOYSA-N 0.000 claims description 3
- BMVWCPGVLSILMU-UHFFFAOYSA-N 5,6-dihydrodibenzo[2,1-b:2',1'-f][7]annulen-11-one Chemical compound C1CC2=CC=CC=C2C(=O)C2=CC=CC=C21 BMVWCPGVLSILMU-UHFFFAOYSA-N 0.000 claims description 3
- 150000001540 azides Chemical class 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 claims description 3
- 239000012279 sodium borohydride Substances 0.000 claims description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- AOUOVFRSCMDPFA-QSDJMHMYSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O AOUOVFRSCMDPFA-QSDJMHMYSA-N 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 238000007259 addition reaction Methods 0.000 claims description 2
- FSEXLNMNADBYJU-UHFFFAOYSA-N alpha-Phenylquinoline Natural products C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=N1 FSEXLNMNADBYJU-UHFFFAOYSA-N 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 229940043267 rhodamine b Drugs 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 55
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 239000000047 product Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 24
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 22
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 16
- 238000002390 rotary evaporation Methods 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- 239000003960 organic solvent Substances 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- 102000003952 Caspase 3 Human genes 0.000 description 9
- 108090000397 Caspase 3 Proteins 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000000862 absorption spectrum Methods 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000000295 emission spectrum Methods 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002292 fluorescence lifetime imaging microscopy Methods 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- WZJYKHNJTSNBHV-UHFFFAOYSA-N benzo[h]quinoline Chemical compound C1=CN=C2C3=CC=CC=C3C=CC2=C1 WZJYKHNJTSNBHV-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 229910021135 KPF6 Inorganic materials 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000002503 iridium Chemical class 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000021419 recognition of apoptotic cell Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QQOWHRYOXYEMTL-UHFFFAOYSA-N triazin-4-amine Chemical class N=C1C=CN=NN1 QQOWHRYOXYEMTL-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0033—Iridium compounds
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6402—Atomic fluorescence; Laser induced fluorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/18—Metal complexes
- C09K2211/185—Metal complexes of the platinum group, i.e. Os, Ir, Pt, Ru, Rh or Pd
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N2021/6495—Miscellaneous methods
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
The invention provides a method for detecting an apoptosis process based on FRET effect, which mainly comprises the following steps: preparing a phosphorescent iridium complex with long service life as a donor D, preparing a short-service-life organic fluorescent small molecular compound as an acceptor A, wherein FRET effect exists between the D and the A; respectively connecting a donor D and an acceptor A to two ends of a peptide chain which can be cut by caspase only existing in the apoptosis process through a bioorthogonal reaction to form a D-A type probe, wherein the D-A type probe can be assembled outside cells and then implanted into the cells, and can also be directly assembled inside the cells; and detecting the change of the service life of the donor D or the receptor A in the D-A type probe by utilizing a confocal imaging or service life imaging technology so as to judge the apoptosis process of the cell. The invention can be applied to each stage of cell apoptosis, can distinguish each stage of cell apoptosis, and has very important application prospect in the fields of cell imaging, biomarkers, sensing and the like.
Description
Technical Field
The invention belongs to the technical field of organic photoelectric materials, and particularly relates to a D-A type probe which is based on FRET effect and can be used for detecting apoptosis and a detection application thereof in an apoptosis process.
Background
Apoptosis, also known as programmed cell death, is a natural or physiological death phenomenon of cells under the control of a series of endogenous genes, plays an important role in the aspects of guiding the formation of embryos, maintaining the balance of normal cells, regulating the growth and development of organisms, naturally aging and the like, and the specific pathways and the complex details involved in the apoptosis process are not completely understood so far. Therefore, it is very important to explore different methods for studying the apoptosis process and its specific details.
In the prior art, the detection of apoptotic cells mainly applies gel electrophoresis technology and flow cytometry, and whether the cells are apoptotic or not is judged according to the molecular change of the cells during apoptosis. Although these techniques provide useful information, they are based on the analysis of the apoptosis end point and do not allow direct and real-time observation of the apoptotic process. At present, the detection of the apoptosis process mainly utilizes the fluorescence imaging technology to detect typical characteristics in the apoptosis process, such as: changes in the cell surface Phosphatidylserine (PS) and mitochondrial membrane potential in the early stages of apoptosis, chromatin fragmentation in the late stages of apoptosis, etc. This type of technique requires determination of apoptosis by multiple results, and cannot detect each stage of apoptosis by a single probe, with the possibility of detecting false positives.
On the other hand, although the advantages of fluorescence imaging technology are outstanding, the disadvantages thereof, such as: the intensity of probe fluorescence (or phosphorescence) strongly depends on concentration, is strongly interfered by biological background fluorescence, is easily photobleached in a short time, emission bands of fluorescent probes tend to overlap, limiting the simultaneous use of multiple probes, and the like. However, fluorescence (or phosphorescence) lifetime is an inherent property of fluorescent materials, and is independent of concentration, photobleaching and excitation intensity, and compared with fluorescence imaging, fluorescence lifetime imaging technology has the advantages of wide fluorescence lifetime interval range, high resolution, small interference from background fluorescence, small overlapping range, simultaneous use and the like, and has gradually become an influential detection means in cell biology.
Disclosure of Invention
The object of the present invention is to provide a method for detecting an apoptotic process based on the FRET effect, aiming to detect an apoptotic process more efficiently and directly.
The technical solution of the invention is as follows: a method for detecting apoptotic processes based on FRET effects comprising the steps of:
s1, preparation of phosphorescent iridium complexes with long lifetimes as donors D: firstly, preparing a product which can perform bio-orthogonal reaction with azide, then connecting the product with p-nitrophenyl chloroformate, reacting the product with a substance containing amino to generate an auxiliary ligand, and then performing coordination reaction on the auxiliary ligand and an iridium dichloro bridge to prepare the phosphorescent iridium complex.
S2, preparing an organic fluorescent small molecular compound as an acceptor A, wherein the service life of the acceptor A is shorter than that of a donor D, and FRET effect exists between the acceptor A and the donor D; firstly, a product which can perform bio-orthogonal reaction with norbornene is prepared and then is connected to the organic fluorescent micromolecule compound with short service life and containing carboxyl through condensation reaction.
S3, respectively connecting the donor D and the receptor A to two ends of a peptide chain to form a D-A type probe through a bioorthogonal reaction, wherein the peptide chain is a peptide chain which can be sheared by caspase only existing in the apoptosis process, and the D-A type probe can be assembled outside cells and then implanted inside the cells or directly assembled inside the cells;
s4, detecting the life change of a donor D in the D-A type probe by using a confocal imaging or life imaging technology, and judging the apoptosis process of the cell; or detecting the life change of the receptor A in the D-A type probe to judge the apoptosis process of the cell.
Further, step S1 is carried out by reacting dibenzosuberone with trimethylsilyldiazomethane at-78 deg.C to obtain product 2; 2 is reduced by sodium borohydride to prepare a product 3; adding liquid bromine to the double bond in the product 3 through addition reaction to obtain a product 4; the product 4 reacts with LDA to prepare a product 5; the product 5 can be substituted with p-nitrophenyl chloroformate to obtain a product 6; oxidizing 4,4 '-dimethyl-2, 2' -bipyridine by selenium dioxide to obtain a product 8; the product 8 reacts with hydroxylamine hydrochloride to obtain a product 9; the product 9 is subjected to ammoniation reaction to prepare a product 10; the product 10 and the product 6 are subjected to substitution reaction to prepare an auxiliary ligand 11; the auxiliary ligand reacts with the phenylquinoline dichloro bridge to prepare the donor Ir-DIBO.
Further, step S2 is a method in which the amino group of p-cyanobenzylamine is protected with di-tert-butyl dicarbonate to obtain product 2; the product 2 reacts with acetonitrile, Zn (OTf)2 and hydrazine monohydrate to prepare a product 3; removing amino protecting groups from the product 3 under the action of concentrated hydrochloric acid to obtain amino tetrazine; the amino group on the amino tetrazine and the carboxyl group on the rhodamine B are subjected to condensation reaction to prepare the receptor tetrazine rhodamine, namely TR.
Further, the donor D has the following structural formula
Wherein the C ^ N ligand is any one of the following:
further, the receptor A has the following structural formula
Wherein A is any one of the following carboxyl-containing organic fluorescent small molecular compounds:
further, the D-A type probe has the following structural formula
Wherein XXXXXX is a connecting peptide chain selected from WEHD, LEHD, DETD, DEVD, DEHD, VEHD, LETD, LEHD.
Further, step S4 is a method, in which the peptide chain connects the long-lived donor and the short-lived acceptor, and the energy of the donor is transferred to the acceptor due to the FRET effect, so that the lifetime of the whole probe is reduced compared with that of the probe in the presence of only the donor; when the cell is in apoptosis, Caspase in the cell is activated, the Caspase cuts off a probe with a specific peptide chain so as to block FRET effect, and the phosphorescence life of the donor is recovered;
the peptide chain connects a long-life donor and a short-life acceptor, and the energy of the donor is transferred to the acceptor due to the FRET effect, so that the life of the whole probe is reduced compared with that of the probe in the presence of only the acceptor; when the cell is in apoptosis, Caspase in the cell is activated, and after the activation, the Caspase cuts off a probe with a specific peptide chain so as to block FRET effect and restore the phosphorescence lifetime of the receptor.
Therefore, the invention provides a brand-new method for detecting the apoptosis process by constructing a D-A type probe with FRET effect, wherein the donor of the probe is an iridium complex with longer service life, the acceptor is an organic fluorescent small molecular compound with shorter service life compared with the iridium complex, and the connecting peptide XXXX is a peptide chain which can be cut by caspase enzyme only existing in apoptosis. When the donor and the acceptor are linked together by a peptide chain, the energy of the donor is transferred to the acceptor due to the FRET effect, resulting in a decrease in the lifetime of the entire probe; when the cell is in the apoptosis stage, caspase is activated, the polypeptide connected with the probe is sheared, the FRET effect disappears, and the phosphorescence life of the donor is recovered, thereby achieving the purpose of detecting the apoptosis process of the cell.
The invention has very important application prospect in the fields of cell imaging, biological marking, sensing and the like, and the technical effects are shown as follows:
(1) the invention can detect the change of the service life of the probe by combining the time resolution technology, and has higher resolution than the traditional fluorescence intensity;
(2) the probe can be excited by visible light, so that the damage of an excitation light source to a biological sample is weakened;
(3) the probe can be applied to the detection of each stage of cell apoptosis, can distinguish each stage of cell apoptosis, can be simultaneously used by multiple probes, does not influence the performance of each other, has good biocompatibility, and is a good biological cell probe;
(4) the probe can be assembled in cells through bioorthogonal reaction, the assembly efficiency is high, and further purification is not needed.
Drawings
FIG. 1 is a UV-visible absorption spectrum and an emission spectrum of donor Ir-DIBO;
FIG. 2 is an image of the phosphorescent lifetime in a cell in the presence of donor Ir-DIBO alone;
FIG. 3 is a UV-VIS absorption spectrum of a rhodamine-containing acceptor;
FIG. 4 is phospholifetime imaging in cells for detection of caspase-3 enzyme probe;
FIG. 5 is life-span imaging after addition of apoptosis-inducing agents (STS);
FIG. 6 is a graph comparing the intracellular phosphorescence lifetime imaging in the presence of donor Ir-DIBO alone and probe phosphorescence lifetime distribution curves before and after apoptosis induced by STS addition.
Detailed Description
Researches show that the Caspase plays an essential role in the apoptosis process, and the Caspase exists in the whole apoptosis process all the time, and the apoptosis process is actually a cascade amplification reaction process of irreversibly hydrolyzing a substrate by the Caspase. In the process of apoptosis, the activation time periods of Caspase are different, and the existence of Caspase directly reflects the stage of apoptosis. The invention utilizes fluorescence (or phosphorescence) life imaging technology to detect and distinguish apoptosis stage by constructing a D-A type probe which is based on FRET effect and can detect whether Caspase exists; meanwhile, by changing the sequence of the connecting peptide chain of the probe, various Caspase enzymes can be detected, the detection accuracy is greatly improved, and the effect of simplifying the detection is achieved.
According to the technical scheme of the invention, the D-A type probe for detecting the apoptosis process is characterized in that a long-life donor and a short-life acceptor are connected together through a specific peptide chain, and the energy of the donor is transferred to the acceptor due to the FRET effect, so that the service life of the whole probe is reduced compared with that of the whole probe in the presence of only the donor. When the cell is apoptotic, Caspase in the cell is activated, the enzyme exists in different stages of the cell apoptosis, a plurality of Caspase enzymes detected at present exist in each stage of the cell apoptosis respectively, namely, the Caspase is activated respectively in different stages of the cell apoptosis; after activation, the enzyme cleaves the probe with the specific peptide chain to block the FRET effect and the phosphorescent lifetime of the donor is restored.
Alternatively, when a specific peptide chain links a long-lived donor and a short-lived acceptor together, the energy of the acceptor is transferred to the donor by FRET effect, thereby decreasing the lifetime of the entire probe compared to the case where only the acceptor is present. When the cell is in apoptosis, Caspase in the cell is activated, and after the activation, the enzyme cuts off a probe with a specific peptide chain so as to block FRET effect and restore the phosphorescence lifetime of the receptor.
Therefore, the cell apoptosis condition can be judged by detecting and comparing the phosphorescence lifetime of the donor or the acceptor by using the phosphorescence lifetime imaging technology.
The D-A type probe for detecting the apoptosis process has the following structural formula:
wherein, the connecting peptide chain XXXX is a peptide chain which can be cut by caspase enzyme only existing in the process of apoptosis, the left side and the right side of the peptide chain are respectively connected with a donor and an acceptor, the donor is a long-life iridium complex, and the acceptor is a short-life organic fluorescent small molecular compound. The linker peptide chain used in this example was a DEVDGK sequence directed against caspase-3 enzyme in late apoptosis, and was synthesized by Shanghai Qianzhan Biotech Co., Ltd.
Specifically, the donor preparation process is: firstly, obtaining a product 5 which can perform bio-orthogonal reaction with azide through a series of reactions, then connecting the product 5 with p-nitrophenyl chloroformate, reacting with a substance 10 containing amino to generate an auxiliary ligand 11, and performing coordination reaction on the auxiliary ligand 11 and an iridium dichloro bridge to prepare the long-life iridium complex serving as a probe donor. The synthetic route is as follows:
the preparation process of the receptor comprises the following steps: firstly, a product 4 which can perform bio-orthogonal reaction with norbornene is generated through a series of reactions, and the product 4 is connected to a short-life organic fluorescent micromolecule compound 6 containing carboxyl through condensation reaction with carboxyl, so that the preparation of the short-life organic fluorescent micromolecule serving as a probe acceptor is completed. The synthetic route is as follows:
the above donor and acceptor lifetimes are significantly different, with the donor lifetime being long and the acceptor lifetime being short. After the donor and the receptor are obtained through synthesis, the donor and the receptor can be injected into cells, and in order to avoid purification, the embodiment adopts an intracellular self-assembly mode; and (3) completing the assembly of the probe in the cell through a bioorthogonal reaction, and then detecting the change of the service life of the probe in the apoptotic cell through a confocal imaging and service life imaging technology. When the cells are assembled, the assembly is rapid and efficient, and further purification is not needed; in addition, during specific application, a proper donor and an acceptor can be selected to improve FRET efficiency, detection of caspase family enzymes can be realized by changing a connecting peptide chain, the detection sensitivity is high, mutual influence is avoided, and the detection can be used simultaneously, so that each stage of apoptosis can be distinguished.
The technical solution of the present invention will be described in detail with reference to the accompanying drawings by way of specific examples. It should be noted that the following are only exemplary embodiments to which the technical concept of the present invention is applied, and all technical solutions formed by equivalent substitutions or equivalent changes are within the scope of the present invention.
Preparation of first, auxiliary ligand
The overall preparative route for ancillary ligand 11 is shown below:
1. preparation of Compound 2
A solution of trimethylsilyldiazomethane (21.9mmol) in dichloromethane (20mL) was slowly added to a solution of dibenzosuberone (14.0mmol) and boron trifluoride etherate (21.0mmol) in dichloromethane (15mL) under nitrogen, the reaction mixture was stirred at-78 deg.C for 2 hours, then poured into ice water, the aqueous phase was extracted with dichloromethane, the organic phase was collected and washed with brine, after drying over anhydrous magnesium sulfate, the magnesium sulfate was filtered off, the organic solvent was removed by rotary evaporation, and the crude product was purified on a silica gel column to give white solid 2, yield: 78 percent. 1H NMR (400MHz, CDCl3) δ 8.26(d, J7.9 Hz,1H),7.52-7.20(m,7H),7.05(q, J16 Hz,12Hz,2H),4.06(s, 2H).
2. Preparation of Compound 3
Sodium borohydride (20mmol) was slowly added to a mixture of compound 2(10mmol) in ethanol and tetrahydrofuran (1:1, v/v, 120mL), stirred at room temperature for 7 hours, acetic acid (1mL) was slowly added to quench the reaction, the solvent was removed by rotary evaporation, the residue was dissolved in dichloromethane (100mL), the resulting solution was washed with brine (100mL) and extracted with dichloromethane, the organic phase was collected and dried over anhydrous magnesium sulfate, the magnesium sulfate was removed by filtration, and the organic solvent was removed by rotary evaporation to give 3 as a white solid (used directly in the next reaction without further purification) in 100% yield. 1H NMR (400MHz, CDCl3) δ 7.46(d, J6.7 Hz,1H), 7.25-7.07 (m,7H),6.85(q, J32 Hz,8Hz,2H),5.29(q, J16 Hz,1H),3.39(q, 2H).
3. Preparation of Compound 4
Liquid bromine (10mmol) was slowly added dropwise to a chloroform (50mL) solution of compound 3(10mmol) under a nitrogen atmosphere, and after stirring at room temperature for 0.5 hour, the organic solvent was removed by rotary evaporation, and the crude product was purified by silica gel column to give 4 as a pale yellow oil in a yield of 45%. 1H NMR (400MHz, CDCl3) δ 7.69-7.38 (m,2H), 7.27-6.88 (m,6H), 5.88-5.76 (m,1H), 5.47-5.41 (m,1H),5.31(dd, J14.4, 5.4Hz,1H), 3.77-3.56 (m,1H), 3.12-2.83 (m, 1H).
4. Preparation of Compound 5
Under nitrogen atmosphere, LDA tetrahydrofuran solution (2.0M; 8mL, 16mmol) was slowly added dropwise to compound 4(4.0mmol) tetrahydrofuran (40mL), stirred at-78 deg.C for 1 hour, transferred to room temperature and stirred for 1 hour, after the reaction was completed, water (0.5mL) was added dropwise to quench the reaction, the organic solvent was removed by rotary evaporation, and the crude product was purified by silica gel column to give 5 as a white solid in 68% yield. 1H NMR (400MHz, CDCl3) δ 7.75(d, J7.8 Hz,1H), 7.47-7.28 (m,7H),4.64(s,1H),3.11(dd, J14.7, 2.2Hz,1H), 2.99-2.83 (m, 1H).
5. Preparation of Compound 6
P-nitrophenyl chloroformate (2mmol) and pyridine (5mmol) were added to a solution of compound 5(1mmol) in dichloromethane (30mL), and after stirring at room temperature for 4 hours, the mixture was washed with brine, the collected organic phase was dried over anhydrous magnesium sulfate, the magnesium sulfate was removed by filtration, the organic solvent was removed by rotary evaporation, and the crude product was purified on a silica gel column to give 6 as a white solid in 82% yield. 1H NMR (400MHz, CDCl3) δ 8.35-8.05 (m,2H),7.62(d, J7.9 Hz,1H), 7.54-7.27 (m,9H),5.58(s,1H),3.34(dd, J15.4, 2.1Hz,1H),3.01(ddd, J16.0, 14.6,3.1Hz, 1H).
6. Preparation of Compound 8
Dissolving 4,4 '-dimethyl-2, 2' -bipyridine (10mmol) and selenium dioxide (10mmol) in 1, 4-dioxane (300mL), heating to 102 ℃, reacting for 24 hours, filtering to remove black solids when the reaction is finished, removing the solvent by rotary evaporation and dissolving in ethyl acetate, filtering to remove the solids by suction again, and removing the solvent by rotary evaporation to obtain a white solid 8 with a yield of 57%.
7. Preparation of Compound 9
Dissolving the compound 8(3mmol) in methanol (10mL), adding hydroxylamine hydrochloride (11mmol), potassium carbonate (15mmol) and water (10mL) respectively, heating to 80 ℃ for reaction for 1 hour, cooling to room temperature after the reaction is completed, pouring into cold water to precipitate a white solid, filtering and recrystallizing in methanol to obtain a white solid 9, wherein the yield is as follows: 90 percent. 1H NMR (400MHz, CDCl3) δ 8.70(d, J5.4 Hz,1H),8.61(s,1H),8.54(d, J5.1 Hz,1H),8.21(d, J12.7 Hz,2H),7.49(dd, J5.1, 1.6Hz,1H),7.18(d, J5.1 Hz,1H),5.34(t, J4.9 Hz,1H),2.46(s, 3H).
8. Preparation of Compound 10
Heating and refluxing a mixed solution of the compound 9(2mmol), ammonium acetate (5mmol), ammonia water (10mmol), ethanol (5mL) and water (5mL) for 3 hours, adding zinc powder (10mmol) in portions after the reaction starts for 30 minutes, cooling to room temperature after the reaction is completed, filtering to remove solids, removing ethanol by rotary evaporation, then adding sodium hydroxide (35mmol), generating a white precipitate, extracting an aqueous phase with dichloromethane, collecting the organic phase, drying with anhydrous magnesium sulfate, filtering to remove magnesium sulfate, and removing an organic solvent by rotary evaporation to obtain a white solid 10 with a yield of 90%. 1H NMR (400MHz, CDCl3) δ 8.62(d, J5.0 Hz,1H),8.53(d, J5.0 Hz,1H),8.33(s,1H),8.23(s,1H),7.29(d, J5.0 Hz,1H),7.14(d, J4.9 Hz,1H),3.96(d, J17.8 Hz,2H),2.44(s, 3H).
9. Preparation of ancillary ligands 11
Compound 6(2mmol) and compound 10(2mmol) were dissolved in dichloromethane (10mL) under nitrogen atmosphere and triethylamine (1mL) was added, stirred at room temperature for 12 hours, extracted with dichloromethane, the organic phase was collected, dried over anhydrous magnesium sulfate, filtered to remove magnesium sulfate, the organic solvent was removed by rotary evaporation and the crude product was purified on silica gel column to give 11 as a white solid in 78% yield. 1H NMR (400MHz, DMSO) δ 8.61-8.49 (m,2H),8.38(t, J6.2 Hz,1H), 8.36-8.19 (m,2H),7.61(d, J7.0 Hz,1H), 7.48-7.22 (m,9H),7.07(s,1H),4.31(t, J7.2 Hz,2H),3.24(d, J13.1 Hz,1H),2.79(dt, J28.3, 22.3Hz,1H),2.40(s, 3H).
Preparation of donor Ir-DIBO with main ligand of benzoquinoline
As in the above formula, 11(0.2mmol) and an iridium dichloro bridge (0.08mmol) were stirred and refluxed at 55 ℃ overnight in a mixed solvent of methylene chloride and methanol (1:3, v/v,4mL) under a nitrogen atmosphere, after which the reaction solution was cooled to room temperature, KPF6(1.4mmol) was added thereto and stirred for 4 hours, after the completion of the reaction, the organic solvent was removed by rotary evaporation, and the resulting solid was purified by column to obtain Ir-DIBO as a yellow powdery solid in a yield of 45%. 1H NMR (400MHz, CDCl3) δ 8.26-7.90 (m,11H), 7.76-7.56 (m,3H),7.33(t, J11.8 Hz,8H), 7.28-7.10 (m,6H),6.98(dq, J21.6, 7.1Hz,2H),6.81(q, J7.1 Hz,2H),6.51(ddd, J26.4, 13.3,5.7Hz,3H), 5.49-5.34 (m,1H), 4.53-4.34 (m,2H),3.23(dd, J13.3, 9.8Hz,1H),2.88(dd, J16.3, 5.0, 1H),2.46(d, J5H, 3H).
Ultraviolet-visible absorption spectrum and emission spectrum of donor Ir-DIBO
The ultraviolet-visible light spectrum and absorption spectrum testing concentrations of Ir-DIBO adopted by the invention are both 10 mu M, the testing solvent is PBS solution containing 1% DMSO with the pH value of 7.2-7.4, and the excitation wavelength is 405nm when the emission spectrum is tested.
The UV-VIS absorption and emission spectra of Ir-DIBO are shown in FIG. 1. The solid line in the figure is the ultraviolet-visible light absorption spectrum of the complex, and it can be seen that the complex shows stronger absorption in both the ultraviolet region of 250-380nm and the visible blue region of 400-500nm, and particularly the complex can be excited by visible light, so that the damage of the excitation light source to cells is greatly reduced when cell imaging experiments are performed; the dotted line is the emission spectrum of the complex, and it can be seen that the emission peak is broad, with the peak occurring at 588 nm.
Imaging of phosphorescent lifetime in cells in the presence of donor Ir-DIBO alone
The cells adopted by the invention are all human cervical carcinoma HeLa cells. The digested cells were seeded in petri dishes at 37 ℃ with 5% CO2The culture was continued for 24 hours under the conditions of (1) to allow adhesion. Cells were washed out of necrotic tissue with PBS solution, incubated with cell culture medium of Ir-DIBO (5. mu.M, 1% DMSO) for 2 hours, washed three times with PBS solution and imaged for phosphorescence lifetime.
Images of the phosphorescent lifetime in cells in the presence of donor Ir-DIBO alone are shown in figure 2. The complex Ir-DIBO is excited by a 405nm laser, and the emission in the 550-650nm interval is collected, as shown in (a) in FIG. 2, the phosphorescence is uniformly distributed in cytoplasm, and the material is shown to enter the cells; (b) for the phosphorescence lifetime profile of the material measured by FLIM technique, the peak is found at 688ns, so the phosphorescence lifetime τ of Ir-DIBO in the cell can be considered as 688 ns.
Preparation of penta-and aminotriazines (as shown below)
1. Preparation of Compound 2
A solution of p-cyanobenzylamine (10mmol) in water (10mL) was added to a solution of NaOH (30mmol) and di-tert-butyl dicarbonate (10mmol) in water (10mL) and stirred at room temperature for 16 hours, a white precipitate formed, which was filtered and the white residue washed with water (50mL) and then dried under vacuum to give the white product 2 in 100% yield. 1H NMR (400MHz, CDCl3) δ 8.54(d, J8.4 Hz,2H),7.49(d, J8.3 Hz,2H),5.01(s,1H),4.43(d, J5.8 Hz,2H),3.09(s,3H),1.45(d, J23.4 Hz, 9H).
2. Preparation of Compound 3
Under a nitrogen atmosphere, Compound 2(2mmol), acetonitrile (39.25mmol), Zn (OTf)2(0.96mmol) and hydrazine monohydrate (96mmol) were mixed together, heated to 70 ℃ for reaction for 72h, cooled to room temperature after completion of the reaction, sodium nitrite (39mmol) was dissolved in 5ml of water and slowly added dropwise to the above solution, followed by adjustment of pH 3 with 1M HCl, extraction with dichloromethane, collection of the organic phase, drying over anhydrous magnesium sulfate, filtration to remove magnesium sulfate, rotary evaporation to remove the organic solvent, and purification of the crude product over a silica gel column to give 3 as a reddish-purple solid in 40% yield. 1H NMR (400MHz, CDCl3) δ 8.55(d, J8.4 Hz,2H),7.50(d, J8.4 Hz,2H),5.00(s,1H),4.43(d, J5.7 Hz,2H),3.09(s,3H),1.45(d, J23.2 Hz, 9H).
3. Preparation of Compound 4
A4M solution of hydrochloric acid (8.0mmol) was added to a solution of compound 3(0.26mmol) in dichloromethane (4mL), stirred for 1 hour, and the organic solvent was removed by rotary evaporation to give a magenta solid 4, (i.e., aminotetrazine), in 100% yield. 1H NMR (400MHz, D2O) δ 8.32(t, J6.9 Hz,2H),7.57(D, J8.3 Hz,2H),4.15(D, J23.1 Hz,2H),2.85(D, J66.1 Hz, 3H).
Preparation of hexa-receptor Tetrazine Rhodamine (TR)
As shown above, compound 5(Rhodamine) (0.6mmol), 1- (3-dimethylaminopropyl) -3-Ethylcarbodiimide (EDC) (0.6mmol) and 4-Dimethylaminopyridine (DMAP) (0.4mmol) were dissolved in 5mL of dichloromethane, stirred at room temperature for 30 minutes, then added to a solution of 4 (aminotetrazine, 0.4mmol) in N, N-2-methylformamide, stirred at room temperature for 24 hours, extracted with water and dichloromethane, the organic phase was collected, dried over anhydrous magnesium sulfate, filtered to remove magnesium sulfate, rotary evaporated to remove the organic solvent, and the crude product was purified by silica gel column to give the final product 6 (i.e., acceptor tetrazine Rhodamine) in 30% yield. 1H NMR (400MHz, CDCl3) δ 8.19(dd, J8.5, 1.9Hz,2H), 8.01-7.94 (m,1H), 7.52-7.41 (m,2H),7.17(dd, J8.5, 4.0Hz,2H), 7.14-7.09 (m,1H),6.26(dd, J11.0, 5.7Hz,4H),6.04(dt, J8.6, 2.7Hz,2H),4.40(s,2H),3.21(q, J7.1 Hz,8H),3.05(s,3H),1.03(t, J7.1 Hz, 12H).
Seventhly, ultraviolet-visible absorption spectrum of receptor Tetrazine Rhodamine (TR)
The Tetrazine Rhodamine (TR) spectrum test concentration adopted by the invention is 2mM, and the test solvent is PBS mixed with 1% DMSO, and the pH value of the PBS is 7.2-7.4.
The ultraviolet-visible absorption spectrum of the receptor Tetrazine Rhodamine (TR) is shown in FIG. 3. From the figure, it can be seen that the organic fluorescent small molecule shows stronger absorption at 450-600nm, and the peak appears at 540 nm. The absorption spectrum of the acceptor TR has an overlap with the emission spectrum of the donor Ir-DIBO, the condition of 'donor-acceptor pair' is satisfied, and FRET effect exists between the TR and the Ir-DIBO, so that energy can be transferred from the donor to the acceptor.
The self-assembly of the probe is accomplished by the bioorthogonal reaction of the donor and the acceptor in the cell as shown in the following figure:
eighth, phospho-luminescence lifetime imaging of probes for detecting caspase-3 enzyme in cells
Inoculating the digested HeLa cells of human cervical cancer into a culture dish, and culturing at 37 deg.C with 5% CO2The culture was continued for 24 hours under the conditions of (1) to allow adhesion. Necrotic cells were washed with PBS solution and incubated with cell culture media with caspase-3 probe (10. mu.M, 2% DMSO)Cells were washed three times with PBS solution for 3 hours and then imaged for phosphorescence lifetime.
Phospholifetime imaging of probes used to detect caspase-3 enzyme in cells is shown in FIG. 4. The complex Ir-DIBO is excited by a 405nm laser, and the emission at 550-650nm is collected, as shown in (a) in FIG. 4, the phosphorescence is uniformly distributed in the cytoplasm, which shows that the material enters the cells; (b) for the phosphorescence lifetime profile of the material, which can be measured by FLIM technique, it can be seen that the peak is 513ns, and therefore, the phosphorescence lifetime τ of Ir-DIBO in the cell can be regarded as 513 ns.
Nine, imaging lifetime after addition of apoptosis inducer Staurosporine (STS)
Inoculating the digested HeLa cells of human cervical cancer into a culture dish, and culturing at 37 deg.C with 5% CO2The culture was continued for 24 hours under the conditions of (1) to allow adhesion. After washing the necrotic cells with PBS solution, the cells were incubated with a cell culture solution of caspase-3 probe (10. mu.M, 2% DMSO) for 3 hours, then 2. mu.L of STS (1. mu.M) was added and incubated for 10 hours, and after washing three times with PBS solution, phosphorescence lifetime imaging was performed.
Lifetime imaging after addition of apoptosis-inducing agent (STS) is shown in FIG. 5. caspase-3 probe was excited by 405nm laser and collected at 550-650nm emission, as shown in FIG. 4 (a), the phosphorescence was uniformly distributed in the cytoplasm, indicating that the material had entered the cell; (b) in order to measure the phosphorescence lifetime distribution of the material by FLIM technology, it can be seen that the peak value is 668ns, because cell apoptosis is induced after STS is added, caspase-3 enzyme in the cell is activated, the peptide chain sequence in the probe is cut, the FRET effect existing between donor and acceptor is blocked, and the lifetime is prolonged, and it can be seen from the figure that tau is 668 ns.
The phosphorescent lifetime in cells imaged in the presence of donor Ir-DIBO alone and the probe phosphorescent lifetime distribution before and after apoptosis induced by STS addition are shown in fig. 6. As is evident from the figure, the phosphorescent lifetime in the cell is highest in the presence of donor Ir-DIBO alone, corresponding to the dashed line in the figure, τ 688 ns; when Ir-DIBO and TR are connected together by a DEVDGK peptide chain, due to the FRET effect, the energy of Ir-DIBO is transferred to TR, so that the service life of the Ir-DIBO is shortened, and the service life tau is 513ns corresponding to a solid line in the figure; when the apoptosis inducer STS is added, apoptosis is induced, caspase-3 enzyme is activated, and specific cleavage is performed on the peptide chain DEVDGK, so that FRET effect is blocked, energy transfer is eliminated, the service life is prolonged, and at the moment, tau is 668ns corresponding to a triangular line in the figure.
The above description is only a preferred embodiment of the present invention, and the scope of the present invention is not limited to the above embodiment, but equivalent modifications or changes made by those skilled in the art according to the present disclosure should be included in the scope of the present invention as set forth in the appended claims.
Claims (8)
1. A method for detecting apoptotic processes based on FRET effects comprising the steps of:
s1, preparing a phosphorescent iridium complex with long service life as a donor D;
s2, preparing an organic fluorescent small molecular compound as an acceptor A, wherein the service life of the acceptor A is shorter than that of a donor D, and FRET effect exists between the acceptor A and the donor D;
s3, respectively connecting the donor D and the receptor A to two ends of a peptide chain to form a D-A type probe through a bioorthogonal reaction, wherein the peptide chain is a peptide chain which can be sheared by caspase only existing in the apoptosis process, and the D-A type probe is assembled outside cells and then implanted into the cells or directly assembled inside the cells;
s4, detecting the life change of a donor D in the D-A type probe by using a confocal imaging or life imaging technology, and judging the apoptosis process of the cell; or detecting the life change of the receptor A in the D-A type probe to judge the apoptosis process of the cell.
2. Method for detecting apoptotic processes based on FRET effect according to claim 1, characterized in that: the method of the step S1 is that firstly, a product which can generate bio-orthogonal reaction with azide is prepared, then the product is connected with p-nitrophenyl chloroformate, and then the product reacts with a substance containing amino to generate an auxiliary ligand, and the auxiliary ligand and an iridium dichloro bridge are subjected to coordination reaction to prepare the phosphorescent iridium complex.
3. Method for detecting apoptotic processes based on FRET effect according to claim 2, characterized in that: the method of step S1 is that dibenzosuberone is used as raw material, and reacts with trimethylsilyl diazomethane at-78 ℃ to obtain product 2; 2 is reduced by sodium borohydride to prepare a product 3; adding liquid bromine to the double bond in the product 3 through addition reaction to obtain a product 4; the product 4 reacts with LDA to prepare a product 5; the product 5 can be substituted with p-nitrophenyl chloroformate to obtain a product 6; oxidizing 4,4 '-dimethyl-2, 2' -bipyridine by selenium dioxide to obtain a product 8; the product 8 reacts with hydroxylamine hydrochloride to obtain a product 9; the product 9 is subjected to ammoniation reaction to prepare a product 10; the product 10 and the product 6 are subjected to substitution reaction to prepare an auxiliary ligand 11; the auxiliary ligand reacts with the phenylquinoline dichloro bridge to prepare the donor Ir-DIBO.
4. Method for detecting apoptotic processes based on FRET effect according to claim 1, characterized in that: the method of step S2 is to prepare a product that can undergo bio-orthogonal reaction with norbornene, and then to attach it to the short-lived organic fluorescent small molecule compound having a carboxyl group through condensation reaction.
5. Method for detecting apoptotic processes based on FRET effect according to claim 4, characterized in that: step S2 is a process in which di-tert-butyl dicarbonate is used to protect the amino group on p-cyanobenzylamine to produce product 2; the product 2 reacts with acetonitrile, Zn (OTf)2 and hydrazine monohydrate to prepare a product 3; removing amino protecting groups from the product 3 under the action of concentrated hydrochloric acid to obtain amino tetrazine; the amino group on the amino tetrazine and the carboxyl group on the rhodamine B are subjected to condensation reaction to prepare the receptor tetrazine rhodamine, namely TR.
6. Method for detecting apoptotic processes based on FRET effect according to claim 1, characterized in that: the donor D has the following structural formula I or II
Wherein the C ^ N ligand is any one of the following:
7. method for detecting apoptotic processes based on FRET effect according to claim 1, characterized in that: the receptor A has the following structural formula
Wherein A is any one of the following carboxyl-containing organic fluorescent small molecular compounds:
8. method for detecting apoptotic processes based on FRET effect according to claim 1, characterized in that: the D-A type probe has the following structural formula
Wherein XXXXXX is a connecting peptide chain selected from WEHD, LEHD, DETD, DEVD, DEHD, VEHD, LETD, LEHD.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810366318.XA CN108732147B (en) | 2018-04-23 | 2018-04-23 | Method for detecting apoptosis process based on FRET effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810366318.XA CN108732147B (en) | 2018-04-23 | 2018-04-23 | Method for detecting apoptosis process based on FRET effect |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108732147A CN108732147A (en) | 2018-11-02 |
| CN108732147B true CN108732147B (en) | 2021-01-19 |
Family
ID=63939711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810366318.XA Active CN108732147B (en) | 2018-04-23 | 2018-04-23 | Method for detecting apoptosis process based on FRET effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108732147B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109916871B (en) * | 2019-04-03 | 2021-06-29 | 福建师范大学 | FRET efficiency quantitative measurement method applied to apoptosis detection |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828106B2 (en) * | 1999-02-26 | 2004-12-07 | Cyclacel Limited | Methods and compositions using coiled binding partners |
| WO2001046209A1 (en) * | 1999-12-20 | 2001-06-28 | Fluorrx, Inc. | Fluorescent probes |
| EP1401425B1 (en) * | 2001-07-03 | 2006-08-16 | Valeriy Prof. Dr. Tatarsky | Organometallic anti-tumour agent |
| CA2776295A1 (en) * | 2009-09-02 | 2011-03-10 | Kansas State University Research Foundation | Mri and optical assays for proteases |
| AU2015274589B2 (en) * | 2014-06-11 | 2020-12-03 | Board Of Regents, The University Of Texas System | Texaphyrin-Pt(IV) conjugates and compositions for use in overcoming platinum resistance |
| CN105694851B (en) * | 2016-03-08 | 2018-07-27 | 武汉大学 | A kind of cancer target diagnosis and treatment fluorescence probe |
| US9840526B1 (en) * | 2016-07-29 | 2017-12-12 | University Of Macau | Iridium(III)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent |
| CN106397488B (en) * | 2016-08-31 | 2019-01-08 | 南京邮电大学 | A kind of ratio fluorescent fluorine ion probe and its preparation and application |
-
2018
- 2018-04-23 CN CN201810366318.XA patent/CN108732147B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108732147A (en) | 2018-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0973036B1 (en) | Homogeneous luminescence assay method based on energy transfer | |
| US9139868B2 (en) | Silicon and germanium dyes for use in genetic identity | |
| JP5638734B2 (en) | Labeling dye for biomolecule, labeling kit, and method for detecting biomolecule | |
| US20150166791A1 (en) | Fluorescent polymethine cyanine dyes | |
| Xue et al. | Ratiometric fluorescent sensors for detecting zinc ions in aqueous solution and living cells with two-photon microscopy | |
| US9091692B2 (en) | Fluorescent dye | |
| CN1902490B (en) | Method of detecting biological molecules, and labeling dye and labeling kit used for the same | |
| JP5539635B2 (en) | Fluorescent dye | |
| CN104629754A (en) | Carbazole ratio-dependent pH fluorescence probe, and preparation method and application thereof | |
| CN101631796B (en) | Compound having structure derived from mononucleoside or mononucleotide, nucleic acid, labeling substance, and method and kit for detection of nucleic acid | |
| CN108732147B (en) | Method for detecting apoptosis process based on FRET effect | |
| Cserép et al. | NIR Mega‐Stokes Fluorophores for Bioorthogonal Labeling and Energy Transfer Systems–An Efficient Quencher for Daunomycin | |
| US5958673A (en) | Fluorescent dye | |
| KR20190056300A (en) | Labeling dye and kit comprising the same | |
| EP2157088A1 (en) | Indicyanine dyes and the derivatives thereof for analysing biological micromolecules | |
| US20120016128A1 (en) | Rhodamine lactone phosphoramidites and polymers | |
| Natyrov et al. | Synthesis of Unsymmetrical Polymethine Cyanine Fluorescent Dyes for Nucleic Acid Analysis by Real-Time PCR | |
| CN109369646B (en) | Near-infrared ratio type fluorescent molecular rotor, preparation method and application thereof in detecting intracellular viscosity and protein denaturation | |
| JP2016196608A (en) | Fluorescent dye | |
| Kramer et al. | Comparative Studies of Different Quinolinone Derivatives as Donors in Fluorescence‐Resonance‐Energy Transfer (FRET)–Systems in Combination with a (Bathophenanthroline) ruthenium (II) Complex as Acceptor | |
| US20120010404A1 (en) | Oxazine dyes with improved aqueous solubility | |
| RU2725884C2 (en) | Deoxyuridine triphosphates marked with zwitterionic indocyanine dyes | |
| WO2002012867A1 (en) | Fluorescent probe for magnesium ion determination | |
| Farat et al. | Novel xanthene-like dyes: synthesis and spectral properties | |
| US20140200333A1 (en) | Dendron reporter molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 210003, 66 new model street, Gulou District, Jiangsu, Nanjing Applicant after: NANJING University OF POSTS AND TELECOMMUNICATIONS Address before: 210023 9 Wen Yuan Road, Ya Dong new town, Nanjing, Jiangsu. Applicant before: NANJING University OF POSTS AND TELECOMMUNICATIONS |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |